Newsroom | 5206 results

Sorted by: Latest

Diabetes
-

Tidepool Showcases New Real-World Clinical Data and Landmark Women’s Health Initiative at ADA 2026

PALO ALTO, Calif.--(BUSINESS WIRE)--Tidepool, the nonprofit leader advancing innovation in diabetes technology, today unveiled new clinical insights and research initiatives in conjunction with the American Diabetes Association’s (ADA) 86th Scientific Sessions. The company’s presentation slate focuses on the immediate utility of real-world data and Tidepool’s ongoing commitment to closing gaps in women’s health research. Today’s insights demonstrate sustained progress in the adoption of accessi...
-

OrsoBio to Present Preclinical and Clinical Data from its Mitochondrial Protonophore Portfolio at the American Diabetes Association’s 2026 Scientific Sessions

MENLO PARK, Calif.--(BUSINESS WIRE)--At ADA 2026, OrsoBio to share clinical and preclinical data highlighting potential multi-system benefits of mitochondrial protonophore mechanism....
-

Verdiva Bio Presents Preclinical Data on Investigational Obesity Drug Candidates at the American Diabetes Association 86th Scientific Sessions

LONDON & SAN FRANCISCO--(BUSINESS WIRE)--Verdiva Bio Limited (“Verdiva Bio” or “the Company”), a clinical-stage biotechnology company advancing a scalable, once-weekly oral obesity product pipeline, today announced new preclinical data for VRB-103, a once-weekly oral amylin receptor-selective amylin analog, and VRB-104, a unimolecular amylin and GLP-1 receptor dual agonist. These data are being presented in poster sessions at the 86th Scientific Sessions of the American Diabetes Association (AD...
-

CicadaBio Announces Oral Presentation on CC-18, a First-in-Class GLP-1/ActRII Fusion Protein Designed for Muscle-Preservation Weight Loss, at ADA 2026

SHANGHAI--(BUSINESS WIRE)--CicadaBio today announced that new preclinical data for CC-18, its investigational GLP-1/anti-ActRII dual-pathway fusion protein, were shared during an oral presentation at the American Diabetes Association (ADA) Scientific Sessions 2026. The data demonstrated robust weight reduction, preservation of lean mass, reduced weight regain following treatment discontinuation and the potential for extended dosing intervals. CC-18 is designed to address a growing challenge in...
-

Tandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During Pregnancy

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care receives CE mark for AID systems in Europe to include use in type 1 diabetes during pregnancy and adults with type 2 diabetes....
-

Glooko Introduces the First and Only Pump Settings EHR Integration to Bring Insulin Pump Data Directly Into Clinical Workflows

PALO ALTO, Calif.--(BUSINESS WIRE)--Glooko, Inc., a global digital health company focused on helping clinicians address the growing challenges of glycemic safety and diabetes management across the care continuum, today announced the launch of its Insulin Pump Settings Electronic Health Record (EHR) Integration, a new and first-of-its-kind capability in its latest software release that visualizes critical insulin pump configuration data directly into the clinical workflow. For clinics caring for...
-

Phase III FIND‑CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today full results from the Phase III FIND-CKD trial investigating KERENDIA® (finerenone) in adults with non-diabetic chronic kidney disease (nd-CKD) who were also receiving background standard of care. In the trial, KERENDIA met the primary endpoint by showing a significant reduction in the rate of kidney disease progression, as measured by estimated glomerular filtration rate (eGFR) slope (mean annual change from baseline to month...
-

Riassunto: Una dialisi peritoneale a concentrazione stabile grazie al sistema Carry Life UF ha aumentato di quasi tre volte l'ultrafiltrazione e di quasi dieci volte la rimozione del sodio rispetto alla CAPD con destrosio al 2,5%, migliorando nel contempo ...

LUND, Svezia--(BUSINESS WIRE)--  Una dialisi peritoneale a concentrazione stabile grazie al sistema Carry Life UF ha aumentato di quasi tre volte l'ultrafiltrazione e di quasi dieci volte la rimozione del sodio rispetto alla CAPD con destrosio al 2,5%, migliorando nel contempo l'efficienza del glucosio e favorendo una migliore gestione dei fluidi nei pazienti PD Triomed AB oggi ha annunciato i risultati positivi dello studio multicentrico, prospettico, randomizzato, crossover volto a valutare l...
-

Le système de dialyse péritonéale (DP) à concentration constante Carry Life UF a presque triplé l'ultrafiltration et multiplié par dix l'élimination du sodium par rapport à la dialyse péritonéale continue (CAPD) utilisant du dextrose à 2,5 %, ...

LUND, Suède--(BUSINESS WIRE)--  Le système de dialyse péritonéale (DP) à concentration constante Carry Life UF a presque triplé l'ultrafiltration et multiplié par dix l'élimination du sodium par rapport à la dialyse péritonéale continue (CAPD) utilisant du dextrose à 2,5 %, tout en améliorant l'efficacité du glucose et en optimisant la gestion des fluides chez les patients sous DP Triomed AB a annoncé aujourd’hui avoir obtenu des résultats positifs suite à une étude prospective, multicentrique,...
-

Samenvatting: PD met stabiele concentratie met het Carry Life UF-systeem verhoogde ultrafiltratie bijna drievoudig en natriumverwijdering bijna tienvoudig vergeleken met CAPD met 2,5% dextrose, terwijl het de glucose-efficiëntie verbeterde en beter ...

LUND, Zweden--(BUSINESS WIRE)--  PD met stabiele concentratie met het Carry Life UF-systeem verhoogde ultrafiltratie bijna drievoudig en natriumverwijdering bijna tienvoudig vergeleken met CAPD met 2,5% dextrose, terwijl het de glucose-efficiëntie verbeterde en beter vloeistoffenbeheer bevorderde bij PD-patiënten Triomed AB maakte vandaag positieve resultaten bekend uit een prospectief, multi-center, gerandomiseerd cross-over onderzoek dat peritoneale dialyse met stabiele concentratie aan de ha...